非霍奇金淋巴瘤新型免疫治疗药物的研究进展  

Progress of novel immunotherapy agents in non-Hodgkin lymphoma

作　　者：张娅(综述)[1] 王欣(审校)[1] 

机构地区：[1]山东大学附属省立医院血液科,济南250021

出　　处：《白血病．淋巴瘤》2016年第12期764-768,共5页Journal of Leukemia & Lymphoma

基　　金：国家自然科学基金（81473486、81270598）

摘　　要：近年来，新型靶向药物的研发及相关临床试验一直是非霍奇金淋巴瘤（NHL）的研究热点。随着对NHL免疫治疗研究的深入，新型免疫靶向治疗药物不断推出，且多项药物的早期研究显示出了临床获益。文章从细胞表面抗原的靶向单克隆抗体、细胞信号转导通路的靶向治疗及淋巴瘤微环境的靶向治疗等方面对NHL新型免疫治疗药物的最新研究进展进行综述。Novel targeted drugs and clinical trails have become the research highlights of non- Hodgkin lymphoma （NHL） recently. With further studies on immunotherapy in NHL, a number of novel immunotherapeutic targeted agents have been developed, some of which also had showed clinical benefit in early-stage study. The advances on novel immunotherapeutic targeted agents in NHL will be comprehensively reviewed in this paper from three aspects, including the targeted monoclonal antibody of cell surface antigen, the targeted therapy of cell signal transduetion pathway and lymphoma microenvironment.

关 键 词：淋巴瘤 非霍奇金 免疫疗法 靶向治疗 

分 类 号：R733.1[医药卫生—肿瘤]